New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: GlobeNewswire
SOUTHPORT, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading assay and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, announced today the launch of the MockV® RVLP Kit. This kit enables bioprocess scientists to quantify the removal of Retrovirus-Like Particles (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines during biopharmaceutical manufacturing. The kit includes a highly purified and concentrated stock solution of RVLPs along with the necessary reagents for accurate and reliable RVLP quantification. Viral contamination is an inherent risk during the manufacture of biopharmaceutical products such as antibodies, gene therapies, vaccines, and plasma derivatives. Whether introduced initially from raw materials or later through specific manufacturing operations, unmitigated viral contamination has led to serious health im
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production [Yahoo! Finance]Yahoo! Finance
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionBusiness Wire
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024GlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Should You Sell Maravai LifeSciences (MRVI)? [Yahoo! Finance]Yahoo! Finance
MRVI
Earnings
- 2/22/24 - Beat
MRVI
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/16/24 - Form 4
- MRVI's page on the SEC website